Generic Manufacturers May Gain Edge In New Patent Challenge Procedure At PTO
Executive Summary
Apotex’s challenge of Alcon’s Vigamox patent put PTO’s new inter partes review proceeding in the spotlight; 45 petitions have been filed in the biopharma sector.
You may also be interested in...
Patent Bill Aims For Trolls, But Will It Snare Rx Firms Instead?
Rep. Bob Goodlatte’s Innovation Act would delay discovery, require more information to file suits, which could increase the time and expense of pursuing infringement cases.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.